← Back to Search

Remote CGM Monitoring for Type 1 Diabetes

N/A
Waitlist Available
Led By Priya Prahalad, MD, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: birth to < 21 years of age
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will test whether increased contact between patients and their care team can improve diabetes outcomes. Continuous glucose monitor data will be used to proactively reach out to patients and their families for more frequent dose adjustments.

Who is the study for?
This trial is for children and young adults up to 21 years old who have been newly diagnosed with Type 1 Diabetes within the last month. Participants must be seen at Stanford Children's Diabetes Clinic, agree to share their continuous glucose monitor (CGM) data for remote monitoring, and plan to continue their follow-up care at the same clinic.Check my eligibility
What is being tested?
The study aims to see if more contact between patients and healthcare providers through a system called GluVue can help manage diabetes better in the first year after diagnosis. This involves integrating CGM data into the patient's electronic medical record for closer monitoring.See study design
What are the potential side effects?
Since this trial focuses on remote monitoring of existing CGM devices rather than testing new medications or treatments, there are no direct side effects from interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am younger than 21 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Contacts with the care provider
Secondary outcome measures
Hemoglobin A1c

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with Type 1 DiabetesExperimental Treatment1 Intervention
Participants will wear a continuous glucose monitor (CGM) and receive remote monitoring of the CGM data by the clinical care team.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,380 Previous Clinical Trials
17,333,443 Total Patients Enrolled
Priya Prahalad, MD, PhDPrincipal InvestigatorStanford University

Media Library

Remote Monitoring of CGM Data Clinical Trial Eligibility Overview. Trial Name: NCT03968055 — N/A
Type 1 Diabetes Research Study Groups: Patients with Type 1 Diabetes
Type 1 Diabetes Clinical Trial 2023: Remote Monitoring of CGM Data Highlights & Side Effects. Trial Name: NCT03968055 — N/A
Remote Monitoring of CGM Data 2023 Treatment Timeline for Medical Study. Trial Name: NCT03968055 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age limit for participants in this trial extend to those who are retired?

"To be eligible for this particular trial, applicants must aged 0 to 21. Out of the 1,195 total trials, 227 are for those under 18 and 968 are for seniors above 65."

Answered by AI

Could I potentially qualify to be a part of this research project?

"We are looking for 100 individuals with type 1 diabetes mellitus that are below the age of 21. The participants must also agree to follow-up care at the Stanford Children's Diabetes Clinic and CGM data integration into the electronic medical record (EMR) for remote monitoring."

Answered by AI

Are we currently recruiting for this research project?

"No, this particular study is not actively recruiting patients according to the latest information available on clinicaltrials.gov. This site was last updated on 3/15/2021 and shows that the trial was initially posted on 3/25/2019. Although this specific trial is not looking for candidates right now, there are 1,312 other trials that are currently open to participants."

Answered by AI
~2 spots leftby Jun 2024